COVID-19

Ainos Announces Successful Manufacturing of VELDONA GMP Clinical Batch by Swiss Pharmaceutical

Subsequent Phase Involves Completion of Chemistry, Manufacturing, and Controls (CMC) InformationAinos Intends to Submit Investigational New Drug Applications to the…

1 year ago

Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept

Proof of Concept – Evaxion’s AI-Immunology™ platform demonstrates success in designing precision cancer vaccines in hematological cancers by targeting a…

1 year ago

Nanox Announces Third Quarter of 2023 Financial Results and Provides Business Update

Reports progress towards global supply chain development and commercial deployment Ended the third quarter of 2023 with cash, cash equivalents,…

1 year ago

BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC

SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the…

1 year ago

Optimi Health Achieves Genetics Milestone and Completes Psilocybin Extract Validation and Stability Testing

Optimi Health Psilocybe cubensis Optimi Health welcomes eight new strains of Psilocybe cubensis to its genetics library. VANCOUVER, British Columbia,…

1 year ago

Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)

FOSTER CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), a late-stage clinical biopharmaceutical company…

1 year ago

Tonix Pharmaceuticals to Present at Two Upcoming Investor Conferences in December

CHATHAM, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products…

1 year ago

Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

Results from the 600 mg MAD cohort for IMVT-1402 similar to previously disclosed results from the 300 mg MAD cohort…

1 year ago

Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

Results from the 600 mg MAD cohort for IMVT-1402 similar to previously disclosed results from the 300 mg MAD cohort…

1 year ago

Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent

GIMOTI now holds four listed patents with coverage through 2029SOLANA BEACH, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma,…

1 year ago